1. Bowen D, et al.: Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 120(2):187-200, 2003.

2. Aul C, et al.: Increasing incidence of myelodysplastic syndromes: real or fictitious? Leuk Res 22(1):93-100, 1998.

3. Anderson J: Allogeneic hematopoietic cell transplantation for myelodysplastic and myeloproliferative disorders. In: Thomas E, Blume KG, Formans SJ (eds.) Hematopoietic Cell Transplantation. Malden, MA: Blackwell Science;1999:872-886.

4. Bennett JM, et al.: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51(2): 189-199, 1982.

5. Harris NL, et al.: The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 10(12):1419-1432, 1999.

6. Greenberg P, et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079-2088, 1997.

7. Appelbaum FR, Anderson J: Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 12 (suppl 1):S25-S29, 1998.

8. Deeg HJ, Storer B, Slattery JT, et al.: Conditioning with targeted busulfan and cyclophosphamide for hemopoi-etic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100(4):1201-1207, 2000.

9. Appelbaum FR, et al.: Allogeneic marrow transplantation in the treatment of preleukemia. Ann Intern Med 100(5):689-693, 1984.

related donor should be considered for this procedure as first-line therapy. In this group of patients the outcome of an allogeneic SCT is superior to that of immunosuppressive therapy, with a 75-90% chance of long-term survival. In addition, unlike with immunosuppressive therapy, there is a much lower risk of late relapses and development of clonal disorders. Conditioning regimens for patients undergoing an HLA-identical related donor should preferably be free of irradiation, and it appears that cyclophoshamide combined with ATG is optimal in this setting. Preliminary retrospective analyses suggest that for HLA-identical related transplants for AA, the use of PBSC is associated with a worse outcome compared to bone marrow. Alternate donors should not be considered for front-line therapy and should be limited to patients who have failed immunosuppressive therapy. For alternate donor transplants, the use of cyclophos-phamide with ATG as a conditioning regimen is probably inadequate and further intensification is justified to reduce the risk of graft rejection and improve outcomes. Figure 42.3 outlines an algorithm that could be used to decide on the appropriate management of a patient with SAA or VSAA.

10. Greenberg P, Bishop M, Deeg J: Practice guidelines for myelodysplastic syndromes. Oncology 12:53-80, 1998.

11. Giralt S: Bone marrow transplant in myelodysplastic syndromes: new technologies, same questions. Curr Hematol Rep 3(3):165-172, 2004.

12. de Witte T, et al.: Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110(3):620-630, 2000.

13. Sierra J, et al.: Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100(6):1997-2004, 2002.

14. Sutton L, et al.: Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood 88(1):358-365, 1996.

15. Anderson JE, et al.: Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol 93(1):59-67, 1996.

16. Castro-Malaspina H, et al.: Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 99(6): 1943-1951, 2002.

17. de Witte T, et al.: Genotypically nonidentical related donors for transplantation of patients with myelodys-plastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation. Leukemia 15(12):1878-1884, 2001.

18. Nevill TJ, et al.: Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 92(6):1910-1917, 1998.

19. Runde V, et al.: Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21(3):255-261, 1998.

20. Cutler CS, et al.: A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low risk myelodyspla-sia is associated with improved outcome. Blood, 2004.

21. Anderson JE, et al.: Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 89(7):2578-2585, 1997.

22. Copelan EA, et al.: Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation. Bone Marrow Transplant 25(12):1219-1222, 2000.

23. Appelbaum FR, et al.: Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. Ann Intern Med 112(8):590-597, 1990.

24. Anderson JE, et al.: Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase ll study of busulfan, cyclophos-phamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 14(1):220-226, 1996.

25. Slattery JT, Risler LJ: Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 20(5):543-549, 1998.

26. Andersson BS, et al.: Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone Marrow Transplant 25 (suppl 2):S35-S38, 2000.

27. Giralt S, et al.: Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97(3): 631-637, 2000.

28. Shimoni A, et al.: Allogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect. Curr Oncol Rep 2(2): 132-139, 2000.

29. Parker JE, et al.: Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 119(1):144-154, 2002.

30. Martino R, vBA, Jacobelli S, et al.: Reduced intensity conditioning regimens for allogeneic stem cell transplants from HLA identical siblings in adults with MDS: a comparison with standard myeloablative regimens. A study of the EBMT Chronic Leukemia Working Party (EBMT-CLWP) [abstract]. Blood 102:642, 2003. Abstract.

31. De Lima M, et al.: Non-ablative versus reduced intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome. Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood, 2004.

32. Stuart JS, Cao TM, Sandmaier BM et al.: Efficacy of non-myeloablative allogeneic transplant for patients with MDS and myeloproliferative disorders [abstract]. Blood 102:644, 2003. Abstract.

33. Guardiola P, et al.: Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 99(12): 4370-4378, 2002.

34. del Canizo, MC, et al.: Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry. Bone Marrow Transplant 32(10):987-992, 2003.

35. Ooi, J, et al.: Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood 101(12):4711-4713, 2003.

36. Ooi, J, et al.: Unrelated cord blood transplantation for adult patients with myelodysplastic syndrome-related secondary acute myeloid leukaemia. Br J Haematol 114(4):834-836, 2001.

37. Camitta, BM, et al.: Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood 48(1):63-70, 1976.

38. Storb R, et al.: Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithy-mocyte globulin. Blood 89(10):3890-3891, 1997.

39. Passweg JR, et al.: Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood 90(2):858-864, 1997.

40. Ades L, Mary J-Y, Robin M, et al.: Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood 103(7):2490-2497, 2004.

41. Bacigalupo A, et al.: Treatment of acquired severe aplas-tic anemia: bone marrow transplantation compared with immunosuppressive therapy—The European Group for Blood and Marrow Transplantation experience. Semin Hematol 37(1):69-80, 2000.

42. Marsh JC, Ball SE, Darbyshire P, et al.: Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol 123(5):782-801, 2003.

43. Storb R, et al.: Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 84(3):941-949, 1994.

44. Storb R, et al.: Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant 7(1):39-44, 2001.

45. Deeg HJ, et al.: Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors. Blood 83(11):3417-3418, 1994.

46. Deeg HJ, et al.: Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant 5(4):243-252, 1999.

47. Killick SB, Marsh JC: Aplastic anaemia: management. Blood Rev 14(3):157-171, 2000.

48. Herrera-Garza J, et al.: High-dose peripheral blood stem cell transplant for multitransfused severe aplastic anaemia patients without antithymocyte globulin in the conditioning regimen. Bone Marrow Transplant 24(8): 845-848, 1999.

49. Kernan NA, et al.: Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 328(9):593-602, 1993.

50. Margolis D, et al.: Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults. Br J Haematol 94(1):65-72, 1996.

51. Schrezenmeier H, Bacigalupo A, Aglietta M, et al. Consensus document for treating aplastic anaemia. Consensus document of a group of international experts. In: Schrezenmeier H, Bacigalupo, A (eds.) Aplastic Anaemia, Pathophysiology and Treatment. Cambridge: Cambridge Univ. Press;2000:308-315.

52. Bacigalupo A, et al., Bone marrow transplantation for severe aplastic anemia from donors other than HLA identical siblings: a report of the BMT Working Party. Bone Marrow Transplant 3(6):531-535, 1988.

53. Hows JM, et al.: Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anemia and leukemia. Blood 68(6):1322-1328, 1986.

54. Gluckman E, et al.: Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 337(6):373-381, 1997.

55. Barker JN, et al.: Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 97(10):2957-2961, 2001.

This page intentionally left blank

0 0

Post a comment